Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Firibastat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The firibastat (originally named QGC001) product, a BAPAI candidate-drug, is a prodrug that delivers in the brain the EC33 product, a selective and specific inhibitor of Aminopeptidase A, thus preventing the production of Angiontensin III in the brain.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 28, 2022
Lead Product(s) : Firibastat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Firibastat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : PRA Health Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension (REFRESH)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 23, 2021
Lead Product(s) : Firibastat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : PRA Health Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Firibastat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The aim of the study is to assess the efficacy and the safety of firibastat compared to ramipril. The primary endpoint is the change from baseline in Left Ventricle Ejection Fraction (LVEF) assessed by Cardiac Magnetic Resonance (CMR) after a three-month...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 21, 2021
Lead Product(s) : Firibastat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Firibastat
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Eurofins CDMO
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics in End Stage Renal Disease Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 10, 2021
Lead Product(s) : Firibastat
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Eurofins CDMO
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Firibastat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Phase III Pivotal REFRESH Study is part of firibastat’s Phase III clinical development and aims to assess long-term safety as well as the three-month efficacy after a single daily dose of firibastat 1000mg in treatment resistant hypertensive patients.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 18, 2021
Lead Product(s) : Firibastat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Firibastat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II/ Phase III
Sponsor : Faran
Deal Size : Undisclosed
Deal Type : Collaboration
Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Faran
Details : Under the terms of the agreement, Faran will receive the exclusive rights to market Firibastat for the treatment of difficult-to-treat / resistant hypertension in Greece.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $12.1 million
December 15, 2020
Lead Product(s) : Firibastat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Faran
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Firibastat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Xediton Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Xediton Pharmaceuticals will receive exclusive commercialization rights to firibastat for the treatment of difficult to treat/resistant hypertension in Canada.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $11.3 million
October 28, 2020
Lead Product(s) : Firibastat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Xediton Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Firibastat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Qilu Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Qilu Pharmaceutical will receive the exclusive rights to market firibastat for the treatment of difficult-to-treat / resistant hypertension in China, including Hong Kong and Macau.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $50.0 million
October 19, 2020
Lead Product(s) : Firibastat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Qilu Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Firibastat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : First patient in the Company’s FRESH study (Firibastat in treatment-RESistant Hypertension) in difficult-to-treat(1) or resistant(2) hypertension. The study is being conducted jointly with its partner in Latin America, the Biolab Sanus Pharmaceutical l...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 13, 2020
Lead Product(s) : Firibastat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Firibastat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Firibastat in Treatment-resistant Hypertension
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 20, 2020
Lead Product(s) : Firibastat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable